Abaloparatide

Abaloparatide stimulates osteoblast activity and is licensed for treating postmenopausal women with fracture risk. Here, we discuss the clinical evidence for benefit and also the drug adverse effect profile.

Authors

Publication Details

Journal
Prescriber
Published
2024-11-01
DOI
https://doi.org/10.1002/psb.2160
Primary Topic
Cardiac, Anesthesia and Surgical Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abaloparatide

Steve Chaplin
Prescriber
Cardiac, Anesthesia and Surgical Outcomes
article

Abaloparatide

Steve Chaplin
article en

Abstract

Abaloparatide stimulates osteoblast activity and is licensed for treating postmenopausal women with fracture risk. Here, we discuss the clinical evidence for benefit and also the drug adverse effect profile.

PrescriberVol. 35(6)
Good health and well-being
Openalex Percentile: Top 57%
Cardiac, Anesthesia and Surgical Outcomes
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Abaloparatide — Steve Chaplin · Prescriber (2024) | TGRS Research Map | TGRS